Press Release

Harbour BioMed Appoints Mr. Weihao Xu as Chief Strategy Officer

December 03, 2021

Back to list

Harbour BioMed Appoints Mr. Weihao Xu as Chief Strategy Officer

December 03, 2021

Cambridge, MA, Rotterdam, NL, Suzhou, CN - December 2, 2021

 

Harbour BioMed (“HBM”, HKEX:02142) is pleased to announce the appointment of Mr. Weihao Xu as Chief Strategy Officer (CSO), who will base in San Francisco. Mr. Xu will be the Global Head of Business Development and Corporate Development, responsible for developing and executing strategy for partnership and corporate investment, building innovation capabilities as well as an overall business ecosystem to drive growth. He will also be involved in corporate and product portfolio strategy, and investor relations activities in the US.

 

By joining HBM, Mr Xu will be bringing with him more than 15 years of extensive experience in global capital markets, equity investment and financial management. Before HBM, Mr. Xu served as Chief Finance Officer at Alphamab Oncology, CASI Pharmaceuticals, and 111 Inc. Prior to that, he was active in the investment industry, working as the Portfolio Manager for Matthews Asia and several other international investment institutions, where he was responsible for global equity investments.

 

Mr. Xu holds a master’s degree in Accounting from Columbia Business School. He also completed a certified program in High Impact Cancer Research from Harvard Medical School.

Media and Investor Contact:

Harbio BioMed Public Relations

Phone: +86-21-53399123

E-mail: pr@harbourbiomed.com